维生素D与代谢相关脂肪性肝病的关系及机制

陈丹妮; 王世令; 路红; 郑亚; 王玉平; 任茜

doi:10.12290/xhyxzz.2023-0075

维生素D与代谢相关脂肪性肝病的关系及机制

doi: 10.12290/xhyxzz.2023-0075

陈丹妮^{1, 2},
王世令^{1, 2},
路红^{2, 3},
郑亚^{2, 4},
王玉平^{2, 4},
任茜^{2, 3, 4, ,}

1.
兰州大学第一临床医学院, 兰州 730000
2.
兰州大学第一医院消化科, 兰州 730000
3.
兰州大学第一医院消化内镜中心, 兰州 730000
4.
兰州大学第一医院甘肃省消化系疾病临床医学研究中心, 兰州 730000

基金项目:

甘肃省自然科学基金 21JR7RA381

甘肃省卫生行业科研计划项目 GSWSKY2020-07

兰州大学中央高校基本科研业务费 lzujbky-2021-ct17

兰州大学第一医院院内基金 ldyyyn2019-74

详细信息

通讯作者:
任茜, E-mail: ldyy_renqian@lzu.edu.cn

中图分类号: R575.5; R781.6+3
计量
- 文章访问数: 197
- HTML全文浏览量: 30
- PDF下载量: 80
- 被引次数: 0
出版历程
- 收稿日期: 2023-02-13
- 录用日期: 2023-06-19
- 网络出版日期: 2023-08-04
- 刊出日期: 2023-11-30

Relationship Between Vitamin D and Metabolic Associated Fatty Liver Disease and Its Mechanism

CHEN Danni^{1, 2},
WANG Shiling^{1, 2},
LU Hong^{2, 3},
ZHENG Ya^{2, 4},
WANG Yuping^{2, 4},
REN Qian^{2, 3, 4
, ,}

1.
The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China
2.
Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou 730000, China
3.
Digestive Endoscope Center, The First Hospital of Lanzhou University, Lanzhou 730000, China
4.
Gansu Province Clinical Research Center for Digestive Diseases, The First Hospital of Lanzhou University, Lanzhou 730000, China

Funds:

Natural Science Foundation of Gansu Province 21JR7RA381

Health Industry Research Project of Gansu Province GSWSKY2020-07

Fundamental Research Funds for the Central Universities lzujbky-2021-ct17

Hospital Foundation of Lanzhou University First Hospital ldyyyn2019-74

More Information

Corresponding author: REN Qian, E-mail: ldyy_renqian@lzu.edu.cn

摘要

摘要: 代谢相关脂肪性肝病(metabolic associated fatty liver disease，MAFLD)由非酒精性脂肪性肝病更名而来。关于MAFLD的发病机制，目前普遍接受“多重打击”理论，其涉及遗传与环境因素的相互作用，包括胰岛素抵抗、脂质紊乱、氧化应激、肠道微生物群等。然而，目前尚无获批治疗MAFLD的特效药物。近年来研究发现，维生素D缺乏与代谢综合征和脂肪肝的发生相关，但其具体作用机制尚未明确，可能通过影响肝脏脂质代谢、胰岛素敏感性及促炎细胞因子水平进而导致MAFLD的发生，还可通过免疫功能调节、基因调控参与MAFLD的发生。此外，补充维生素D通过肠-肝轴调节肠道微生物群和胆汁酸代谢，可延缓脂肪肝的进展。基于此，本文就维生素D与MAFLD之间的关系进行阐述，并揭示维生素D在MAFLD发病中的潜在机制，为MAFLD的临床治疗提供新思路。
- 维生素D /
- 代谢相关脂肪性肝病 /
- 维生素D受体
Abstract: Metabolic associated fatty liver disease (MAFLD) was renamed from the nonalcoholic fatty liver disease (NAFLD). In terms of the pathogenesis of MAFLD, the generally accepted theory is "multiple attacks", including insulin resistance, lipid disorder, oxidative stress, intestinal microbiota, etc., which involves the interaction of genetic and environmental factors. However, currently there is no approved drug for MAFLD. Recent studies have found that vitamin D is involved in many metabolic processes and may cause MAFLD by influencing liver lipid metabolism, promoting insulin resistance and inflammatory response, participating in immune regulation, gene regulation and maintaining intestinal homeostasis. Therefore, this article summarizes the relationship between vitamin D and MAFLD, explores the potential role of vitamin D in the pathogenesis of MAFLD, and provides clinical ideas for the treatment of MAFLD.
- vitamin D /
- metabolic associated fatty liver disease /
- vitamin D receptor
注释:

作者贡献：陈丹妮、王世令负责文献检索和论文撰写；路红、郑亚、王玉平负责论文修订；任茜负责论文选题设计。

利益冲突：所有作者均声明不存在利益冲突

HTML全文

图 1 VDD与MAFLD发展之间的潜在途径

AngⅡ：血管紧张素Ⅱ；GLUT4：葡萄糖转运体4；MAPK：丝裂原活化蛋白激酶；NF-κB：核因子κB；TLR：Toll样受体；ANGPTL8：血管生成素样蛋白8；VDR：维生素D受体；SNP：单核苷酸多态性；VDD：维生素D缺乏症；ASBT：回肠顶端钠依赖性胆汁酸共转运体；MAFLD：代谢相关脂肪性肝病

下载: 全尺寸图片幻灯片

参考文献(68)

[1]	Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73: 202-209. doi: 10.1016/j.jhep.2020.03.039
[2]	Paik JM, Golabi P, Younossi Y, et al. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD[J]. Hepatology, 2020, 72: 1605-1616. doi: 10.1002/hep.31173
[3]	Wong RJ, Cheung R. Trends in the Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in the United States, 2011—2018[J]. Clin Gastroenterol Hepatol, 2022, 20: e610- e613. doi: 10.1016/j.cgh.2021.01.030
[4]	Charoenngam N, Holick MF. Immunologic Effects of Vitamin D on Human Health and Disease[J]. Nutrients, 2020, 12: 2097. doi: 10.3390/nu12072097
[5]	Szymczak-Pajor I, Drzewoski J, Śliwińska A. The Molecular Mechanisms by Which Vitamin D Prevents Insulin Resis-tance and Associated Disorders[J]. Int J Mol Sci, 2020, 21: 6644. doi: 10.3390/ijms21186644
[6]	Jiang Z, Pu R, Li N, et al. High prevalence of vitamin D deficiency in Asia: A systematic review and meta-analysis[J]. Crit Rev Food Sci Nutr, 2021: 1-10.
[7]	Rimondi E, Marcuzzi A, Casciano F, et al. Role of vitamin D in the pathogenesis of atheromatosis[J]. Nutr Metab Cardiovasc Dis, 2021, 31: 344-353. doi: 10.1016/j.numecd.2020.08.031
[8]	Dawson-Hughes B, Staten MA, Knowler WC, et al. Intratrial Exposure to Vitamin D and New-Onset Diabetes Among Adults With Prediabetes: A Secondary Analysis From the Vitamin D and Type 2 Diabetes (D2d) Study[J]. Diabetes Care, 2020, 43: 2916-2922. doi: 10.2337/dc20-1765
[9]	Yu S, Song L, Wei Q, et al. Dose-response relationship between serum 25-hydroxyvitamin D and the risk of metabolic syndrome[J]. Clin Nutr, 2021, 40: 1530-1536. doi: 10.1016/j.clnu.2021.02.031
[10]	Cimini FA, Barchetta I, Carotti S, et al. Overview of studies of the vitamin D/vitamin D receptor system in the development of non-alcoholic fatty liver disease[J]. World J Gastrointest Pathophysiol, 2019, 10: 11-16. doi: 10.4291/wjgp.v10.i2.11
[11]	Yuan S, Larsson SC. Inverse Association Between Serum 25-Hydroxyvitamin D and Nonalcoholic Fatty Liver Disease[J]. Clin Gastroenterol Hepatol, 2023, 21: 398-405. e4. doi: 10.1016/j.cgh.2022.01.021
[12]	Zhang JJ, Yu HC, Li Y, et al. Association between serum 25-hydroxy vitamin D concentrations and mortality among individuals with metabolic dysfunction-associated fatty liver disease: a prospective cohort study[J]. Am J Clin Nutr, 2022, 116: 1409-1417. doi: 10.1093/ajcn/nqac260
[13]	Fan X, Wang J, Song M, et al. Vitamin D Status and Risk of All-Cause and Cause-Specific Mortality in a Large Cohort: Results From the UK Biobank[J]. J Clin Endocrinol Metab, 2020, 105: dgaa432.
[14]	Luo L, Ye J, Shao C, et al. Vitamin D Status Presents Different Relationships with Severity in Metabolic-Associated Fatty Liver Disease Patients with or without Hepatitis B Infection[J]. Nutrients, 2022, 14: 2114. doi: 10.3390/nu14102114
[15]	周荃, 李金强, 黎晓武. 维生素D缺乏对非酒精性脂肪性肝炎患者FIB-4指数及病情严重程度的影响[J]. 临床肝胆病杂志, 2022, 38: 1293-1298. https://www.cnki.com.cn/Article/CJFDTOTAL-LCGD202206015.htm
[16]	Ha Y, Hwang SG, Rim KS. The Association between Vitamin D Insufficiency and Nonalcoholic Fatty Liver Disease: A Population-Based Study[J]. Nutrients, 2017, 9: 806. doi: 10.3390/nu9080806
[17]	Patel YA, Henao R, Moylan CA, et al. Vitamin D is Not Associated With Severity in NAFLD: Results of a Paired Clinical and Gene Expression Profile Analysis[J]. Am J Gastroenterol, 2016, 111: 1591-1598. doi: 10.1038/ajg.2016.406
[18]	Manson JE, Cook NR, Lee IM, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease[J]. N Engl J Med, 2019, 380: 33-44. doi: 10.1056/NEJMoa1809944
[19]	Neale RE, Baxter C, Romero BD, et al. The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality[J]. Lancet Diabetes Endocrinol, 2022, 10: 120-128. doi: 10.1016/S2213-8587(21)00345-4
[20]	Wang N, Chen C, Zhao L, et al. Vitamin D and Nonalcoholic Fatty Liver Disease: Bi-directional Mendelian Randomization Analysis[J]. EbioMedicine, 2018, 28: 187-193. doi: 10.1016/j.ebiom.2017.12.027
[21]	El Khoudary SR, Samargandy S, Zeb I, et al. Serum 25-hydroxyvitamin-D and nonalcoholic fatty liver disease: Does race/ethnicity matter? Findings from the MESA cohort[J]. Nutr Metab Cardiovasc Dis, 2020, 30: 114-122. doi: 10.1016/j.numecd.2019.09.004
[22]	Lukenda Zanko V, Domislovic V, Trkulja V, et al. Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial[J]. Diabetes Obes Metab, 2020, 22: 2097-2106. doi: 10.1111/dom.14129
[23]	El Amrousy D, Abdelhai D, Shawky D. Vitamin D and nonalcoholic fatty liver disease in children: a randomized controlled clinical trial[J]. Eur J Pediatr, 2022, 181: 579-586. doi: 10.1007/s00431-021-04243-4
[24]	Gad AI, Elmedames MR, Abdelhai AR, et al. Efficacy of vitamin D supplementation on adult patients with non-alcoholic fatty liver disease: a single-center experience[J]. Gastroenterol Hepatol Bed Bench, 2021, 14: 44-52.
[25]	Rezaei S, Tabrizi R, Nowrouzi-Sohrabi P, et al. The Effects of Vitamin D Supplementation on Anthropometric and Biochemical Indices in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis[J]. Front Pharmacol, 2021, 12: 732496. doi: 10.3389/fphar.2021.732496
[26]	Rasouli N, Brodsky IG, Chatterjee R, et al. Effects of Vitamin D Supplementation on Insulin Sensitivity and Secretion in Prediabetes[J]. J Clin Endocrinol Metab, 2022, 107: 230-240. doi: 10.1210/clinem/dgab649
[27]	Wei Y, Wang S, Meng Y, et al. Effects of Vitamin D Supplementation in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis[J]. Int J Endocrinol Metab, 2020, 18: e97205.
[28]	Carlberg C, Haq A. The concept of the personal vitamin D response index[J]. J Steroid Biochem Mol Biol, 2018, 175: 12-17. doi: 10.1016/j.jsbmb.2016.12.011
[29]	Triantos C, Aggeletopoulou I, Thomopoulos K, et al. Vitamin D-Liver Disease Association: Biological Basis and Mechanisms of Action[J]. Hepatology, 2021, 74: 1065-1073. doi: 10.1002/hep.31699
[30]	Udomsinprasert W, Jittikoon J. Vitamin D and liver fibrosis: Molecular mechanisms and clinical studies[J]. Biomed Pharmacother, 2019, 109: 1351-1360. doi: 10.1016/j.biopha.2018.10.140
[31]	Lockau L, Atkinson SA. Vitamin D's role in health and disease: How does the present inform our understanding of the past?[J]. Int J Paleopathol, 2018, 23: 6-14. doi: 10.1016/j.ijpp.2017.11.005
[32]	Dong B, Zhou Y, Wang W, et al. Vitamin D Receptor Activation in Liver Macrophages Ameliorates Hepatic Inflammation, Steatosis, and Insulin Resistance in Mice[J]. Hepatology, 2020, 71: 1559-1574. doi: 10.1002/hep.30937
[33]	Zhang H, Shen Z, Lin Y, et al. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease[J]. J Biol Chem, 2020, 295: 3891-3905. doi: 10.1074/jbc.RA119.011487
[34]	Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J]. Metabolism, 2016, 65: 1038-1048. doi: 10.1016/j.metabol.2015.12.012
[35]	Marziou A, Philouze C, Couturier C, et al. Vitamin D Supplementation Improves Adipose Tissue Inflammation and Reduces Hepatic Steatosis in Obese C57BL/6J Mice[J]. Nutrients, 2020, 12: 342. doi: 10.3390/nu12020342
[36]	Szymczak-Pajor I, Śliwińska A. Analysis of Association between Vitamin D Deficiency and Insulin Resistance[J]. Nutrients, 2019, 11: 794. doi: 10.3390/nu11040794
[37]	Zeng Y, Luo M, Pan L, et al. Vitamin D signaling maintains intestinal innate immunity and gut microbiota: potential intervention for metabolic syndrome and NAFLD[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 318: G542-G553. doi: 10.1152/ajpgi.00286.2019
[38]	Surdu AM, Pînzariu O, Ciobanu DM, et al. Vitamin D and Its Role in the Lipid Metabolism and the Development of Atherosclerosis[J]. Biomedicines, 2021, 9: 172. doi: 10.3390/biomedicines9020172
[39]	Li R, Guo E, Yang J, et al. 1, 25(OH)₂D₃ attenuates hepatic steatosis by inducing autophagy in mice[J]. Obesity (Silver Spring), 2017, 25: 561-571. doi: 10.1002/oby.21757
[40]	Lim H, Lee H, Lim Y. Effect of vitamin D₃ supplementa-tion on hepatic lipid dysregulation associated with autophagy regulatory AMPK/Akt-mTOR signaling in type 2 diabetic mice[J]. Exp Biol Med (Maywood), 2021, 246: 1139-1147. doi: 10.1177/1535370220987524
[41]	Borges CC, Salles AF, Bringhenti I, et al. Vitamin D Deficiency Increases Lipogenesis and Reduces Beta-Oxidation in the Liver of Diet-Induced Obese Mice[J]. J Nutr Sci Vitaminol (Tokyo), 2018, 64: 106-115. doi: 10.3177/jnsv.64.106
[42]	Marino M, Venturi S, Del Bo C, et al. Vitamin D Counteracts Lipid Accumulation, Augments Free Fatty Acid-Induced ABCA1 and CPT-1A Expression While Reducing CD36 and C/EBPβ Protein Levels in Monocyte-Derived Macrophages[J]. Biomedicines, 2022, 10: 775. doi: 10.3390/biomedicines10040775
[43]	Hosny SS, Ali HM, Mohammed WA, et al. Study of relationship between total vitamin D level and NAFLD in a sample of Egyptian patients with and without T2DM[J]. Diabetes Metab Syndr, 2019, 13: 1769-1771. doi: 10.1016/j.dsx.2019.04.002
[44]	Manna P, Jain SK. Vitamin D up-regulates glucose transporter 4 (GLUT4) translocation and glucose utilization mediated by cystathionine-γ-lyase (CSE) activation and H2S formation in 3T3L1 adipocytes[J]. J Biol Chem, 2012, 287: 42324-42332. doi: 10.1074/jbc.M112.407833
[45]	Elseweidy MM, Amin RS, Atteia HH, et al. Vitamin D3 intake as regulator of insulin degrading enzyme and insulin receptor phosphorylation in diabetic rats[J]. Biomed Pharmacother, 2017, 85: 155-159. doi: 10.1016/j.biopha.2016.11.116
[46]	Borges CC, Salles AF, Bringhenti I, et al. Adverse effects of vitamin D deficiency on the Pi3k/Akt pathway and pancreatic islet morphology in diet-induced obese mice[J]. Mol Nutr Food Res, 2016, 60: 346-357. doi: 10.1002/mnfr.201500398
[47]	Li YC, Kong J, Wei M, et al. 1, 25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system[J]. J Clin Invest, 2002, 110: 229-238. doi: 10.1172/JCI0215219
[48]	Gutierrez-Rodelo C, Arellano-Plancarte A, Hernandez-Aranda J, et al. Angiotensin Ⅱ Inhibits Insulin Receptor Signaling in Adipose Cells[J]. Int J Mol Sci, 2022, 23: 6048. doi: 10.3390/ijms23116048
[49]	Roth CL, Elfers CT, Figlewicz DP, et al. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation[J]. Hepatology, 2012, 55: 1103-1111. doi: 10.1002/hep.24737
[50]	Liu Y, Wang M, Xu W, et al. Active vitamin D supplementation alleviates initiation and progression of nonalcoholic fatty liver disease by repressing the p53 pathway[J]. Life Sci, 2020, 241: 117086. doi: 10.1016/j.lfs.2019.117086
[51]	Zhang X, Shang X, Jin S, et al. Vitamin D ameliorates high-fat-diet-induced hepatic injury via inhibiting pyroptosis and alters gut microbiota in rats[J]. Arch Biochem Biophys, 2021, 705: 108894. doi: 10.1016/j.abb.2021.108894
[52]	Wang H, Mehal W, Nagy LE, et al. Immunological mechanisms and therapeutic targets of fatty liver diseases[J]. Cell Mol Immunol, 2021, 18: 73-91. doi: 10.1038/s41423-020-00579-3
[53]	Ortiz-López N, Fuenzalida C, Dufeu MS, et al. The immune response as a therapeutic target in non-alcoholic fatty liver disease[J]. Front Immunol, 2022, 13: 954869. doi: 10.3389/fimmu.2022.954869
[54]	Sîrbe C, Rednic S, Grama A, et al. An Update on the Effects of Vitamin D on the Immune System and Autoimmune Diseases[J]. Int J Mol Sci, 2022, 23: 9784. doi: 10.3390/ijms23179784
[55]	Czaja AJ, Montano-Loza AJ. Evolving Role of Vitamin D in Immune-Mediated Disease and Its Implications in Autoimmune Hepatitis[J]. Dig Dis Sci, 2019, 64: 324-344. doi: 10.1007/s10620-018-5351-6
[56]	Barrea L, Muscogiuri G, Frias-Toral E, et al. Nutrition and immune system: from the Mediterranean diet to dietary supplementary through the microbiota[J]. Crit Rev Food Sci Nutr, 2021, 61: 3066-3090. doi: 10.1080/10408398.2020.1792826
[57]	Su YB, Li TH, Huang CC, et al. Chronic calcitriol supplementation improves the inflammatory profiles of circulating monocytes and the associated intestinal/adipose tissue alteration in a diet-induced steatohepatitis rat model[J]. PLoS One, 2018, 13: e0194867. doi: 10.1371/journal.pone.0194867
[58]	Tourkochristou E, Mouzaki A, Triantos C. Gene Polymorphisms and Biological Effects of Vitamin D Receptor on Nonalcoholic Fatty Liver Disease Development and Progression[J]. Int J Mol Sci, 2023, 24: 8288. doi: 10.3390/ijms24098288
[59]	García-Monzón C, Petrov PD, Rey E, et al. Angiopoietin-Like Protein 8 Is a Novel Vitamin D Receptor Target Gene Involved in Nonalcoholic Fatty Liver Pathogenesis[J]. Am J Pathol, 2018, 188: 2800-2810. doi: 10.1016/j.ajpath.2018.07.028
[60]	Jaroenlapnopparat A, Suppakitjanusant P, Ponvilawan B, et al. Vitamin D-Related Genetic Variations and Nonalco-holic Fatty Liver Disease: A Systematic Review[J]. Int J Mol Sci, 2022, 23: 9122. doi: 10.3390/ijms23169122
[61]	Arai T, Atsukawa M, Tsubota A, et al. Association of vitamin D levels and vitamin D-related gene polymorphisms with liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease[J]. Dig Liver Dis, 2019, 51: 1036-1042. doi: 10.1016/j.dld.2018.12.022
[62]	Wang M, Wang M, Zhang R, et al. Influences of Vitamin D Levels and Vitamin D-Binding Protein Polymorphisms on Nonalcoholic Fatty Liver Disease Risk in a Chinese Population[J]. Ann Nutr Metab, 2022, 78: 61-72. doi: 10.1159/000522193
[63]	Leung C, Rivera L, Furness JB, et al. The role of the gut microbiota in NAFLD[J]. Nat Rev Gastroenterol Hepatol, 2016, 13: 412-425.
[64]	Barbáchano A, Fernández-Barral A, Ferrer-Mayorga G, et al. The endocrine vitamin D system in the gut[J]. Mol Cell Endocrinol, 2017, 453: 79-87.
[65]	He L, Liu T, Shi Y, et al. Gut Epithelial Vitamin D Receptor Regulates Microbiota-Dependent Mucosal Inflamma-tion by Suppressing Intestinal Epithelial Cell Apoptosis[J]. Endocrinology, 2018, 159: 967-979.
[66]	Singh P, Rawat A, Alwakeel M, et al. The potential role of vitamin D supplementation as a gut microbiota modifier in healthy individuals[J]. Sci Rep, 2020, 10: 21641.
[67]	Kong M, Zhu L, Bai L, et al. Vitamin D deficiency promotes nonalcoholic steatohepatitis through impaired enterohepatic circulation in animal model[J]. Am J Physiol Gastrointest Liver Physiol, 2014, 307: G883- G893.
[68]	Lee PC, Hsieh YC, Huo TI, et al. Active Vitamin D₃ Treatment Attenuated Bacterial Translocation via Improving Intestinal Barriers in Cirrhotic Rats[J]. Mol Nutr Food Res, 2021, 65: e2000937.

施引文献

资源附件(0)

访问统计

点击查看大图

图(1)

计量

文章访问数: 197
HTML全文浏览量: 30
PDF下载量: 80
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

地址：	北京市东城区帅府园1号北京协和医院老楼7号楼 3层302室《协和医学杂志》编辑部
电话：	010-69154261/4262
E - mail：	medj@pumch.cn mjpumch@126.com
期刊网站版权所有：	《协和医学杂志》编辑部京ICP备 11002662

留言板

维生素D与代谢相关脂肪性肝病的关系及机制

doi: 10.12290/xhyxzz.2023-0075

通讯作者:
任茜, E-mail: ldyy_renqian@lzu.edu.cn

计量

Relationship Between Vitamin D and Metabolic Associated Fatty Liver Disease and Its Mechanism

Corresponding author: REN Qian, E-mail: ldyy_renqian@lzu.edu.cn

计量

目录

留言板

维生素D与代谢相关脂肪性肝病的关系及机制

doi: 10.12290/xhyxzz.2023-0075

通讯作者: 任茜, E-mail: ldyy_renqian@lzu.edu.cn

计量

出版历程

Relationship Between Vitamin D and Metabolic Associated Fatty Liver Disease and Its Mechanism

Corresponding author: REN Qian, E-mail: ldyy_renqian@lzu.edu.cn

计量

出版历程

目录

通讯作者:
任茜, E-mail: ldyy_renqian@lzu.edu.cn